Rapid control of secondary hyperparathyroidism with paricalcitol (Zemplar®) capsule in patients on peritoneal dialysis.

被引：0
|
作者：
Qiu, P
Smolenski, O
Fadem, S
Kant, KS
Borneman, L
Hippensteel, R
Williams, LA
Moe, S
机构：
[1] GPRD, Abbott Labs, Abbott Pk, IL USA
[2] Washington Univ, St Louis, MO USA
[3] Nephrol Hosp B Rydygier, Krakow, Poland
[4] Univ Tennessee, Memphis, TN USA
[5] Kidney Associates, Houston, TX USA
[6] Univ Cincinnati, Dialysis Clin Inc, Cincinnati, OH USA
[7] Indiana Univ, Indianapolis, IN 46204 USA
来源：
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2003年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：484A / 484A
页数：1
相关论文
共 50 条
  • [1] Paricalcitol (Zemplar®) capsule controls secondary hyperparathyroidism in chronic hemodialysis patients.
    Llach, F
    Qiu, P
    Ross, EA
    Abboud, H
    Mere, CC
    Wojtak, A
    Hippensteel, R
    Williams, LA
    Block, G
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 198A - 199A
  • [2] Paricalcitol(Zemplar®) capsule controls secondary hyperparathyroidism (SHPT) in CKD stage 5 patients
    Qiu, P
    Gonzalez, EA
    Melnick, JZ
    Williams, LA
    Sprague, SM
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2004, 43 (04) : A38 - A38
  • [3] Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis
    Ross, Edward A.
    Tian, Jin
    Abboud, Hanna
    Hippensteel, Richard
    Melnick, Joel Z.
    Pradhan, Rajendra S.
    Williams, Laura A.
    Hamm, L. Lee
    Sprague, Stuart M.
    [J]. AMERICAN JOURNAL OF NEPHROLOGY, 2008, 28 (01) : 97 - 106
  • [4] Optimized dosing regimen of paricalcitol capsule for the treatment of secondary hyperparathyroidism in dialysis patients
    Ross, Edward
    Abboud, Hannah
    Tian, Jin
    Hippensteel, Richard
    Melnick, Joel
    Williams, Laura
    Hamm, L. Lee
    Sprague, Stuart
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2007, 22 : 190 - 190
  • [5] Paricalcitol (Zemplar®) injection for the treatment of secondary hyperparathyroidism in pediatric hemodialysis patients.
    Kommala, DR
    Benador, N
    Goldstein, S
    Pardes, A
    Mattingly, S
    Amdahl, M
    Greenbaum, L
    Williams, LA
    Salusky, I
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 199A - 199A
  • [6] Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients
    Capuano, Alfredo
    Serio, Vittorio
    Pota, Andrea
    Memoli, Bruno
    Andreucci, Vittorio E.
    [J]. JOURNAL OF NEPHROLOGY, 2009, 22 (01) : 59 - 68
  • [7] Paricalcitol (Zemplar®) capsule reduces iPTH in CKD stage 5 patients with severe (iPTH>1000) secondary hyperparathyroidism.
    Gonzalez, EA
    Qiu, P
    Silberzweig, J
    Hippensteel, R
    Fukumoto, S
    Williams, LA
    Ostrow, D
    Echlin, D
    Batlle, DA
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 199A - 199A
  • [8] Oral paricalcitol versus oral calcitriol in continuous ambulatory peritoneal dialysis patients with secondary hyperparathyroidism
    Ema J. Jamaluddin
    Abdul Halim Abdul Gafor
    Loo Chee Yean
    Rizna Cader
    Rozita Mohd
    Norella C. T. Kong
    Shamsul Azhar Shah
    [J]. Clinical and Experimental Nephrology, 2014, 18 : 507 - 514
  • [9] Oral paricalcitol versus oral calcitriol in continuous ambulatory peritoneal dialysis patients with secondary hyperparathyroidism
    Jamaluddin, Ema J.
    Gafor, Abdul Halim Abdul
    Yean, Loo Chee
    Cader, Rizna
    Mohd, Rozita
    Kong, Norella C. T.
    Shah, Shamsul Azhar
    [J]. CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2014, 18 (03) : 507 - 514
  • [10] Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism
    Llach, F
    Yudd, M
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2001, 38 (05) : S45 - S50
12345